SRR26320076
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | s_150324_4b | EPN | Posterior Fossa EPN | 0.937 |
| 2 | EPT0508 | EPN | Posterior Fossa EPN | 0.928 |
| 3 | BS_N1E0H8YQ | low-grade glioma | — | 0.927 |
| 4 | MNG281 | — | — | 0.926 |
| 5 | EPT0509 | EPN | EPN Tumor | 0.921 |
| 6 | BS_EN2VK7NY | low-grade glioma | — | 0.919 |
| 7 | BS_WRHDP7WF | EPN | Posterior Fossa EPN | 0.919 |
| 8 | BS_8RHPJ740 | EPN | EPN Tumor | 0.916 |
| 9 | TCGA-CN-6020-01A-11R-1686-07 | — | — | 0.915 |
| 10 | SRR8518423 | — | C | 0.915 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 45 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.700 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.620 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.600 | Inavolisib | — uncovered |
| COAGULATION | 0.540 | Binimetinib | — uncovered |
| MYOGENESIS | 0.530 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.510 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.480 | Idelalisib | — uncovered |
| HYPOXIA | 0.470 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.440 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.420 | Inavolisib | — uncovered |
| APOPTOSIS | 0.410 | Idelalisib | — uncovered |
| COMPLEMENT | 0.410 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.410 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.410 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.390 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.380 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.370 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.360 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.350 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.350 | Idelalisib | — uncovered |